Loading clinical trials...
Loading clinical trials...
A Phase 2 Open-label Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With Duchenne Muscular Dystrophy (DMD) Compared to Natural History Controls
Conditions
Interventions
Viltolarsen
Locations
8
United States
Children's Hospital of Richmond at VCU
Richmond, Virginia, United States
The Third Medical Center of PLA General Hospital
Beijing, China
Hunan Children's Hospital
Changsha, China
Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
Roma, Italy
Russian National Research Medical University
Moscow, Russia
Saint Petersburg State Paediatric Medical University
Saint Petersburg, Russia
Start Date
July 1, 2021
Primary Completion Date
June 20, 2023
Completion Date
July 13, 2023
Last Updated
August 20, 2024
NCT06817382
NCT06839469
NCT07037862
NCT07160634
NCT06450639
NCT05016908
Lead Sponsor
NS Pharma, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions